We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+1.9%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$3.17M
AUM Growth
+$561K
Cap. Flow
+$147M
Cap. Flow %
4,647.33%
Top 10 Hldgs %
63.1%
Holding
323
New
68
Increased
74
Reduced
74
Closed
84

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$37.9M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$24.5M
3
MRK icon
Merck
MRK
+$12.3M
4
GILD icon
Gilead Sciences
GILD
+$11.7M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$11.6M

Top Sells

Rank Stock Value
1
LRMR icon
Larimar Therapeutics
LRMR
+$4.64M
2
OCUL icon
Ocular Therapeutix
OCUL
+$3.33M
3
ACGN
Aceragen Inc
ACGN
+$2.48M
4
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$2.06M
5
PRQR icon
ProQR Therapeutics
PRQR
+$1.95M

Sector Composition

Rank Sector Weight
1 Healthcare 9.16%
2 Energy 0.42%
3 Industrials 0.14%
4 Consumer Staples 0.11%
5 Technology 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
276
Xencor
XNCR
$1.48B
– –
-171,275
Closed -$1.59K
VIRX
277
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-19
Closed -$2.91K
VIRX
278
PUT
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-4
Closed -$650
SEEL
279
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– -$26
SEEL
280
PUT
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– -$130
ALIM
281
CALL
DELISTED
Alimera Sciences
ALIM
– –
-46
Closed -$376
ALIM
282
DELISTED
Alimera Sciences
ALIM
– –
-3,333
Closed -$271
ALIM
283
PUT
DELISTED
Alimera Sciences
ALIM
– –
-33
Closed -$266
NBSE
284
CALL
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
– –
-2
Closed -$62
EIGR
285
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-158
Closed -$743
ICPT
286
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-55
Closed -$1.3K
INFI
287
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-5,438
Closed -$79.2K
ACGN
288
DELISTED
Aceragen Inc
ACGN
– –
-6,182
Closed -$2.48M
AMPE
289
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
– –
-469
Closed -$497
AMPE
290
PUT
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
– –
-5
Closed -$497
HSTO
291
DELISTED
Histogen Inc. Common Stock
HSTO
– –
-240
Closed -$347K
ARNA
292
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-27,478
Closed -$1.12M
ARNA
293
PUT
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-415
Closed -$1.74K
GWPH
294
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-250
Closed -$2.02K
GNMX
295
PUT
DELISTED
Aevi Genomic Medicine Inc
GNMX
– –
-145
Closed -$75
ECYT
296
CALL
DELISTED
Endocyte, Inc. Common Stock
ECYT
– –
-159
Closed -$97
ECYT
297
DELISTED
Endocyte, Inc. Common Stock
ECYT
– –
-11,300
Closed -$69
ECYT
298
PUT
DELISTED
Endocyte, Inc. Common Stock
ECYT
– –
-863
Closed -$525
CORI
299
DELISTED
Corium International, Inc.
CORI
– –
-130,732
Closed -$803
ANTH
300
CALL
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
– –
-85
Closed -$131
9 10 11
12
13

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2014 Portfolio in Review

As of Q4 2014, Sabby Management held 323 positions worth $3.17M, up 22% from $2.6M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sabby Management deployed $147M of net new capital in Q4 2014, opening 68 new positions and adding to 74 existing holdings. Its largest new stake was Pfizer: 1,322,658 shares worth $39.1K.

By sector, the portfolio is most concentrated in Healthcare at 9.2% of assets, up from 6.3% a quarter earlier, followed by Energy and Industrials.

On the sell side, the largest reduction was Larimar Therapeutics, an estimated $4.64M trimmed.

  • Sabby Management's largest Q4 2014 buy was Pfizer: 1,322,658 shares worth $39.1K.
  • Sabby Management added most to Achillion Pharmaceuticals in Q4 2014, an estimated $11.6M increase.
  • Sabby Management's biggest Q4 2014 reduction was Larimar Therapeutics, cutting an estimated $4.64M.
  • Sabby Management fully exited Aceragen Inc in Q4 2014, selling an estimated $2.48M.
  • Sabby Management's ten largest holdings make up 63% of its $3.17M portfolio in Q4 2014.
  • Sabby Management opened 68 new positions and closed 84 in Q4 2014.
  • Sabby Management's portfolio value rose 22% quarter-over-quarter to $3.17M.

Based on Sabby Management's 13F filing for Q4 2014, filed 17 Feb 2015.